Literature DB >> 28351154

Use of Continuous-Infusion Ceftolozane/Tazobactam in a Multidrug-Resistant Pseudomonas aeruginosa Urinary Tract Infection in the Outpatient Setting.

Bruce M Jones, Bradley Smith, Christopher M Bland.   

Abstract

Entities:  

Year:  2017        PMID： 28351154     DOI： 10.1177/1060028017701938

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN： 1060-0280            Impact factor:   3.154


× No keyword cloud information.
  3 in total

1.  Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.

Authors:  Maddalena Peghin; Massimo Maiani; Nadia Castaldo; Filippo Givone; Elda Righi; Andrea Lechiancole; Assunta Sartor; Federico Pea; Ugolino Livi; Matteo Bassetti
Journal:  Infection       Date:  2017-10-31       Impact factor: 3.553

2.  Real-world use of ceftolozane/tazobactam: a systematic literature review.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887

3.  Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting.

Authors:  Bruce M Jones; Kathryn Huelfer; Christopher M Bland
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.